Chapter 8: Compatibility Testing. Compatibility Testing A.K.A. crossmatch Defined as all the steps necessary in I.D. and testing of or for potential transfusion in an attempt to provide blood product that survives in vivo and provides a therapeutic effect. Includes: Recipient Identification
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Chapter 8: Compatibility Testing
Major is the one we perform in transfusion medicine.
Incompatible crossmatch indicated by hemolysis or agglutination at any phase of testing.
Most facilities use AHG in combination with electronic information.
Box 8-3, 8-4
Very important to follow protocol of facility and the AABB standards for blood product usage.
Primary cause of incompatibility.
Box 8-5 Emergency release requirements
Registration: Documentation of individual on permanent records- retained indefinitely.
Bullets on pg. 206
Prior to any donation must give educational material which includes information on :
Table 9-2, pg 216, box 9-1 and 9-2
Determined by capillary tube or CuSO4
Informed consent- written consent from donor for procedure and use of blood products
Donor requirements and testing must be met as usual.
Hemapharesis: (Blood , to move)
Whole blood is collected or removed from a donor, separated by mechanical device and the rest is returned to the donor.
Intentional removal of blood for therapeutic purpose, used to treat certain disease processes.
Utilize internal and external controls to verify reactivity or lack of.
Need to know the test that are performed on donor units. (table 10-2)
Western Blot test
Look back method
CPD and CP2D: storage 21 days @ 1-6°C
CPDA-1: storage 35 days @ 1-6°C
Labeling of all products use uniform guideline implemented by FDA. Any additional process to the unit must be identified. Storage is essential. Transport of products is checked and monitored.
Administration of Blood products:
Removal of abnormal cells, plasma or plasma constituents for clinical benefits.
Circulatory overload: cardiopulmonary system exceeds blood volume capacity.
Clinical signs and symptoms:
To prevent we transfuse PRBC instead of whole blood over a long period 4-6 hrs.
3 factors that must be present for HDN to develop:
Treatment for HDN: